Stock Rating Downgrade
The Value Trend Rating for Sarepta Therapeutics Inc (NASDAQ: SRPT) weakened of late from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
On 1/12/24, Sarepta Therapeutics Inc (NASDAQ: SRPT) stock rose modestly by 0.6%, closing at $116.80. However, trading volume in this advance was below average at 72% of normal. Relative to the market the stock has been weak over the last nine months but has risen 23.9% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, SRPT is expected to be a major Value Builder.
Sarepta Therapeutics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Sarepta Therapeutics has a neutral Appreciation Score of 52 and a slightly negative Power Rating of 35, with the Negative Value Trend Rating the result.
Be the first to comment